Literature DB >> 28833651

Fetal major cardiac defects and placental dysfunction at 11-13 weeks' gestation.

I Fantasia1, D Kasapoglu1, T Kasapoglu1, A Syngelaki1, R Akolekar1,2, K H Nicolaides1.   

Abstract

OBJECTIVE: To investigate the relationship between fetal major cardiac defects and markers of placental perfusion and function.
METHODS: This was a prospective screening study in singleton pregnancies at 11-13 weeks' gestation. Uterine artery pulsatility index (UtA-PI), serum pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) were measured and the values were converted into multiples of the normal median (MoM). Median MoM values in fetuses with isolated major cardiac defects were compared with those in fetuses without major defects.
RESULTS: The 50 094 singleton pregnancies fulfilling the entry criteria included 49 898 pregnancies with normal cardiac anatomy and 196 (0.39%) with major congenital cardiac defects: 73 (37.2%) with conotruncal defects, 63 (32.1%) with left ventricular outflow tract defects and 60 (30.6%) with valvular defects. In the group with cardiac defects, compared with controls, there was lower median PAPP-A MoM (0.81 vs 1.00, P < 0.0001) and PlGF MoM (0.78 vs 1.00, P < 0.0001) but no significant difference in UtA-PI MoM (1.01 vs 1.00, P = 0.162).
CONCLUSION: In pregnancies with isolated fetal major cardiac defects, there is evidence of placental dysfunction in the absence of impaired placental perfusion.
Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  congenital heart defect; first-trimester screening; placental growth factor; pregnancy-associated plasma protein-A; uterine artery Doppler

Mesh:

Substances:

Year:  2018        PMID: 28833651     DOI: 10.1002/uog.18839

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

1.  Identification of Gravida Serum Biomarkers for Noninvasive Prenatal Diagnosis Fetal Congenital Heart Disease.

Authors:  Yi Xia; Lin Cheng; Jie Duan; Jianhong Ma; Yuanzhen Zhang
Journal:  J Cardiovasc Transl Res       Date:  2022-09-30       Impact factor: 3.216

2.  Placental DNA Methylation Abnormalities in Prenatal Conotruncal Heart Defects.

Authors:  Jingjing Liu; Yuduo Wu; Hairui Sun; Xiaowei Liu; Xiaoyan Gu; Ying Zhao; Ye Zhang; Jiancheng Han; Yihua He
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

3.  Evidence for uteroplacental malperfusion in fetuses with major congenital heart defects.

Authors:  Julia Binder; Silvia Carta; Julene S Carvalho; Erkan Kalafat; Asma Khalil; Basky Thilaganathan
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

4.  Prenatal Diagnosis of Congenital Heart Diseases and Associations with Serum Biomarkers of Aneuploidy: A Multicenter Prospective Cohort Study.

Authors:  Jeong Ha Wie; You Jung Han; Soo Hyun Kim; Moon Young Kim; Hee Young Cho; Mi-Young Lee; Jin Hoon Chung; Seung Mi Lee; Soo-Young Oh; Joon Ho Lee; Hye Yeon Boo; Geum Joon Cho; Han-Sung Kwon; Byoung Jae Kim; Mi Hye Park; Hyun Mee Ryu; Hyun Sun Ko
Journal:  Yonsei Med J       Date:  2022-08       Impact factor: 3.052

5.  The UA Doppler Index, Plasma HCY, and Cys C in Pregnancies Complicated by Congenital Heart Disease of the Fetus.

Authors:  Xiaona Xu; Baoying Ye; Min Li; Yuanqing Xia; Yi Wu; Weiwei Cheng
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.